Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Top Cited Papers
- 7 June 2012
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (23), 2180-2188
- https://doi.org/10.1056/nejmoa1113538
Abstract
Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas. We tested the anti–basal-cell carcinoma efficacy of vismodegib in a randomized, double-blind, placebo-controlled trial in patients with the basal-cell nevus syndrome at three clinical centers from September 2009 through January 2011. The primary end point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical resection (surgically eligible) with vismodegib versus placebo after 3 months; secondary end points included reduction in the size of existing basal-cell carcinomas. In 41 patients followed for a mean of 8 months (range, 1 to 15) after enrollment, the per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than with placebo (2 vs. 29 cases per group per year, P<0.001), as was the size (percent change from baseline in the sum of the longest diameter) of existing clinically significant basal-cell carcinomas (−65% vs. −11%, P=0.003). In some patients, all basal-cell carcinomas clinically regressed. No tumors progressed during treatment with vismodegib. Patients receiving vismodegib routinely had grade 1 or 2 adverse events of loss of taste, muscle cramps, hair loss, and weight loss. Overall, 54% of patients (14 of 26) receiving vismodegib discontinued drug treatment owing to adverse events. At 1 month, vismodegib use had reduced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tumor-cell proliferation, but apoptosis was not affected. No residual basal-cell carcinoma was detectable in 83% of biopsy samples taken from sites of clinically regressed basal-cell carcinomas. Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome. The adverse events associated with treatment led to discontinuation in over half of treated patients. (Funded by Genentech and others; ClinicalTrials.gov number, NCT00957229.)Keywords
This publication has 25 references indexed in Scilit:
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2012
- Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened InhibitorJournal of Investigative Dermatology, 2011
- Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- miceCarcinogenesis: Integrative Cancer Research, 2009
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell CarcinomaThe New England Journal of Medicine, 2009
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaNature, 2009
- Basal cell carcinomas: attack of the hedgehogNature Reviews Cancer, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma SyndromeCell, 1996
- Nonmelanoma skin cancer in the United States: IncidenceJournal of the American Academy of Dermatology, 1994